PET Tau - Neurodegenerative Disease Imaging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03143374|
Recruitment Status : Recruiting
First Posted : May 8, 2017
Last Update Posted : April 10, 2019
|Condition or disease||Intervention/treatment|
|Parkinson Disease||Device: [18F]T807 (also known as 18F-AV- 1451)|
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells, including Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. [18F]T807 (also known as 18F-AV- 1451) is a specialized radioactive PET tracer that sticks to the tau protein in the brain. In this study, researchers will use [18F]T807 to form images of tau binding in the brain. [18F]T807 is an investigational or experimental imaging agent that has not yet been approved by the Food and Drug Administration for use in brain imaging.
In this study, researchers want to find out how accurate and useful [18F]T807 is in imaging patients who have problems with thinking, remembering, speech, and visual activities, and may be diagnosed with different types of Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. This study will help test how imaging measures may provide information that could be used to determine diagnosis for patients in the future. The results of the PET/CT scan will be compared with other information obtained under related protocols, including brain magnetic resonance imaging (MRI), spinal fluid and cognitive test results.
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||December 2021|
- Device: [18F]T807 (also known as 18F-AV- 1451)
experimental PET/CT scan of the brain. In this scan, imaging is done with specialized cameras that can pick up radiation signals given off by a radioactive tracer and determine where the signals come from.
The tracer used for this study is called FT807 (also known as 18F-AV-1451). FT807 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. FT807 is an experimental tracer that has been studied in patients with known or suspected Alzheimer's disease, Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBS/CBD). In this study, patients will have one (1) [18F]T807 PET/CT scan performed at the University of Pennsylvania. The [18F]T807 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania.
- regional anatomic distribution of PET-tau uptake in dementia syndromes and PET-Tau uptake with neuropsychology and MRI regional GM atrophy at baseline. [ Time Frame: 2 years ]
- •longitudinal neuropsychological and regional MRI decline in dementia syndromes compared to baseline regional PET-tau uptake [ Time Frame: 2 years ]
- • CSF total and phosphorylated (p-tau/t-tau) tau and regional PET-tau uptake in dementia syndromes [ Time Frame: 2 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03143374
|Contact: Courtney M Igne, MSemail@example.com|
|Contact: Katie Pizziketti, BAfirstname.lastname@example.org|
|United States, Pennsylvania|
|University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Courtney M Igne, MS 215-662-3596 email@example.com|
|Contact: Katie Pizziketti, BA 215-349-5873 firstname.lastname@example.org|
|Principal Investigator: Murray Grossman, PhD, MD|
|Principal Investigator:||Murray Grossman, PhD, MD||University of Pennsylvania|